## ARTICLE IN PRESS

Seminars in Cell & Developmental Biology xxx (2014) xxx-xxx



Contents lists available at ScienceDirect

### Seminars in Cell & Developmental Biology

journal homepage: www.elsevier.com/locate/semcdb



#### Review

# Genetically engineered mouse models for epithelial ovarian cancer: Are we there yet?

Viive M. Howell\*

Bill Walsh Translational Cancer Research Laboratory, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, NSW Australia

#### ARTICLE INFO

#### Article history: Available online xxx

# Keywords: Genetically engineered mouse Mouse Transgenic Ovarian cancer Serous Endometrioid

#### ABSTRACT

The development of preclinical spontaneous genetically engineered mouse models (GEMMs) requires an understanding of the genetic basis of the human disease. Such robust models have proven invaluable for increasing understanding of human malignancies as well as identifying new biomarkers and testing new therapies for these diseases. While GEMMs have been reported for ovarian cancer, the majority have proven disappointing overall in their recapitulation of paired genetic and histological features especially for serous ovarian epithelial cancer. This review describes GEMMs for ovarian cancer, in particular, high grade serous ovarian cancer and assesses these in light of recent changes in our understanding of the human malignancy.

© 2014 Elsevier Ltd. All rights reserved.

#### **Contents**

Introd	luction		00
1.1.	Ovarian	rancer	00
1.2.	Mouse	models of ovarian cancer	00
Promo	oter drive	en GEMMS for ovarian cancer	00
2.1.	Overvie	w	00
2.2.	Three p	romoter driven models of serous or poorly differentiated EOC	00
	2.2.1.	Amhr2-SV40Tag – poorly differentiated EOC with serous features	00
	2.2.2.	Amhr2.Cre-Pten <sup>fl/fl</sup> ; Dicer1 <sup>fl/fl</sup> – SEOC	00
	2.2.3.		
2.3.	Epitheli		
	2.3.1.	Oviductal glycoprotein 1 (OGP, OVGP1)	00
	2.3.2.	Ovarian specific promoter-1 (Osp-1)	00
	2.3.3.	Paired box 8 (Pax8)	00
2.4.	Granulo		
	2.4.1.	Anti-Mullerian hormone (AMH)	00
	2.4.2.	Anti-Mullerian hormone receptor 2 (Amhr2/MISIIR)	00
	2.4.3.	Follicle stimulating hormone receptor (Fshr).	00
	2.4.4.	Cytochrome P450, family 19, subfamily a, polypeptide 1 (Cyp-19)	00
	2.4.5.	Progesterone receptor (Pgr)	00
	1.1. 1.2. Promo 2.1. 2.2.	1.1. Ovariar 1.2. Mouse Promoter drive 2.1. Overvie 2.2. Three p 2.2.1. 2.2.2. 2.2.3. 2.3. Epitheli 2.3.1. 2.3.2. 2.3.3. 2.4. Granulo 2.4.1. 2.4.2. 2.4.3. 2.4.4.	1.2. Mouse models of ovarian cancer  Promoter driven GEMMS for ovarian cancer  2.1. Overview  2.2. Three promoter driven models of serous or poorly differentiated EOC  2.2.1. Amhr2-SV40Tag – poorly differentiated EOC with serous features  2.2.2. Amhr2.Cre-Ptenl <sup>[]]</sup> , Dicer1 <sup>[]]</sup> – SEOC  2.2.3. Pax8-TetO-Cre-Tp53 <sup>mut</sup> , Brca1/2 <sup>mut</sup> , Ptenl <sup>[]]</sup> – SEOC  2.3. Epithelial cell promoters  2.3.1. Oviductal glycoprotein 1 (OGP, OVGP1)  2.3.2. Ovarian specific promoter-1 (Osp-1)  2.3.3. Paired box 8 (Pax8).  2.4. Granulosa cell promoters  2.4.1. Anti-Mullerian hormone (AMH)  2.4.2. Anti-Mullerian hormone receptor 2 (Amhr2/MISIIR)  2.4.3. Follicle stimulating hormone receptor (Fshr)  2.4.4. Cytochrome P450, family 19, subfamily a, polypeptide 1 (Cyp-19)

Abbreviations: EOC, epithelial ovarian cancer; SEOC, serous EOC; EEOC, endometrioid EOC; OSE, ovarian surface epithelium; GEMM, genetically engineered mouse model; CRE, Cre recombinase; fl, floxed; LSL, loxP-STOP-loxP; CMV, cytomegalovirus; STIC, tubal *in situ* cancer with *TP53* mutation; rtTA, tetracycline-dependent reverse transactivator; TRE, tetracycline-responsive element; ADCRE, a replication deficient advenovirus altered to express CRE under the control of the CMV promoter; GCT, granulosa cell tumors; NAD, no tumors detected; LS, leiomyosarcoma; S, sarcoma; CIS, carcinoma *in situ*; Hyp, hyperplasia; EEC, endometrioid endometrial cancer; LH, luteinising hormone; FSH, follicle stimulating hormone.

E-mail address: viive.howell@sydney.edu.au

http://dx.doi.org/10.1016/j.semcdb.2014.03.019

1084-9521/@ 2014 Elsevier Ltd. All rights reserved.

Please cite this article in press as: Howell VM. Genetically engineered mouse models for epithelial ovarian cancer: Are we there yet? Semin Cell Dev Biol (2014), http://dx.doi.org/10.1016/j.semcdb.2014.03.019

<sup>\*</sup> Correspondence to: Bill Walsh Translational Cancer Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Level 8, Kolling Building, Royal North Shore Hospital, St Leonards, NSW 2065, Australia. Tel.: +61 2 9926 4758; fax: +61 2 9926 4035.

# ARTICLE IN PRESS

V.M. Howell / Seminars in Cell & Developmental Biology xxx (2014) xxx-xxx

3.	Surgic	ally targeted GEMMS for ovarian cancer	00
	3.1.	Surgical intra-bursal delivery of CRE	00
	3.2.	EOC versus leiomyosarcomas	00
	3.3.	GEMMs of endometrioid EOC	00
	3.4.	Harnessing the power of SV40	00
		3.4.1. SV40 provides a highly penetrant phenotype from a single allele	00
		3.4.2. Utilizing the large T antigen in isolation for RB pathway inactivation: epithelial expression of T <sub>121</sub>	00
4.	Conclu	usions and future perspectives	00
	4.1.	Overview	00
	4.2.	What have we learnt?	00
	4.3.	Are we there yet?	00
	Ackno	owledgements	00
		ences	

TP53	tumor protein p53				
BRCA1/2	breast cancer 1/2, early onset gene				
PTEN	phosphatase and tensin homolog				
RB1	retinoblastoma 1				
ARID1A	A AT rich interactive domain 1A (SWI-like)				
	phosphatidylinositol-4,5-bisphosphate 3-kinase,				
	catalytic subunit alpha				
CTNNB1	catenin, β1				
HNF1	HNF1 homeobox A				
KRAS	Kirsten rat sarcoma viral oncogene homolog				
ERBB2	v-erb-b2 avian erythroblastic leukemia viral onco-				
	gene homolog 2				
BRAF	v-raf murine sarcoma viral oncogene homolog B				
AMH/MI	S anti-Mullerian hormone/Mullerian-inhibiting				
	substance				
AMHR2/I	MISIIR anti-Mullerian hormone receptor				
	2/Mullerian-inhibiting substance receptor 2				
SV40	simian vacuolating virus 40 oncogene				
SV40Tag small t and large T antigens					
Ogp oviductal glycoprotein 1					
Osp-1 ovarian specific promoter-1					
Pax8	paired box 8				
Stk11	Stk11 serine/threonine kinase 11 (Lkb1)				
Fshr	follicle stimulating hormone receptor				
Cyp-19	cytochrome P450, family 19, subfamily a, polypep-				
	tide 1				
Pgr	progesterone receptor				
Apc adenomatosis polyposis coli					
PTTG	pituitary tumor transforming gene				

#### 1. Introduction

#### 1.1. Ovarian cancer

Ovarian cancer is the 7th most common cancer diagnosed in women worldwide, accounting for 4% of all cancers in women [1]. Approximately 90% of ovarian cancers are epithelial in origin and these are further divided according to the histopathological features of the tumor. The majority (70%) of epithelial ovarian cancers (EOCs) are high-grade or Type II serous EOC (SEOC) [2]. These present as moderately or poorly differentiated late stage, highly aggressive neoplasms that spread rapidly and are associated with poor outcome. The other major histopathological EOC subtypes are endometrioid (high and low grade, or Type I and Type II) accounting for 10% of EOC, clear cell (10%), low grade serous (<5%) and mucinous (3%), with the remainder being undifferentiated, mixed or borderline malignant [2].

**Table 1**Molecular aberrations associated with different EOC subtypes [10–12].

Epithelial ovarian cancer subtype	Genes with molecular aberrations
High grade serous (Type II)	TP53, BRCA1/2, RB1
Endometrioid (Type I/II)	PTEN, ARID1A, PIK3CA, CTNNB1
	TP53 (high grade/Type II only)
Clear cell (Type I)	HNF1, ARID1A, PIK3CA
Mucinous (Type I)	KRAS, ERBB2
Low grade serous (Type I)	BRAF, KRAS

Up until the early 2000s the site of origin for all EOC subtypes was thought to be the single layer of epithelial cells lining the ovary (ovarian surface epithelium; OSE) [3]. However, broader analyses of molecular and histopathological features of benign as well as EOC tissues led to the findings that a significant proportion of mucinous EOC may be metastases from the colon rather than primary ovarian carcinomas [4,5], and that endometrioid and clear cell EOC may arise from atypical endometriosis [6,7]. Similarly, the site of origin for high grade SEOC has also come into question, with the secretory cells in the fimbrial end of the fallopian tube now thought to be a major or significant site of origin for SEOC [8,9].

Molecular genetic analysis of these cancers has identified different molecular genetic features and pathways of tumorigenesis for the different subtypes (Table 1). Notable is that TP53 loss or mutation of TP53 is virtually pathognomonic for high grade SEOC [11]. Rare cases of TP53 mutated high grade endometrioid EOC (EEOC) have been reported and their reclassification as SEOC is being considered [13,14]. Other aberrations documented by The Cancer Genome Atlas for high grade SEOC included alteration of the homologous repair pathway in 51% of cases, with BRCA1/2 silencing or mutation found in 33% of these cases; RB signaling alterations in 67% of cases with loss or mutation of RB1 contributing to 10% of these alterations; and altered PI3K/RAS signaling in 47% of tumors with mutation or loss of PTEN in 7% and amplification or mutation of PIK3CA or KRAS in 18% and 11% of tumors, respectively [11]. When taken together, the changing views of the site of origin and the different genetic features of each subtype has led to the notion that the different subtypes are fundamentally distinct diseases (reviewed in [14]). Indeed, while all subtypes involve the ovaries, whether they are all in fact "ovarian cancers" is now in debate.

#### 1.2. Mouse models of ovarian cancer

There is a paucity of robust genetically engineered mouse models (GEMMs) for EOC. Given the changes in our understanding of the origins and genetic features of the different subtypes, this may well be expected as the design of GEMMs requires prior knowledge of both of these aspects of the malignancy. Technical issues compound this changing knowledge; the most significant being the difficulty in specifically and exclusively targeting changes to cells of origin for

Please cite this article in press as: Howell VM. Genetically engineered mouse models for epithelial ovarian cancer: Are we there yet? Semin Cell Dev Biol (2014), http://dx.doi.org/10.1016/j.semcdb.2014.03.019

#### Download English Version:

# https://daneshyari.com/en/article/8480819

Download Persian Version:

https://daneshyari.com/article/8480819

<u>Daneshyari.com</u>